Structural neuroimaging in the detection and prognosis of pre-clinical and early AD.
Structural neuroimaging in the detection and prognosis of pre-clinical and early AD.
复制标题
DOI：
10.3233/ben-2009-0230
复制
发表时间：
2009
影响因子：
2.8
通讯作者：
The Alzheimer's Disease Neuroimaging Initiative
中科院分区：
文献类型：
--
作者：
Fennema-Notestine C;McEvoy LK;Hagler DJ Jr;Jacobson MW;Dale AM;The Alzheimer's Disease Neuroimaging Initiative
目前的研究支持强大的潜力，即使在横截面设计，作为一个有前途的方法，从正常对照的阿尔茨海默氏病（AD）的歧视和轻度认知障碍（MCI）的进展和转换为AD的预测。研究结果表明，在内侧和外侧颞，扣带，顶叶和额中区的结构变化的措施，可能有助于评估治疗的能力，以阻止渐进的结构损失，伴随着临床MCI下降。随着疾病进展风险个体的区域特征得到改善，结合其他神经影像学方式、临床评估和神经医学生物标志物的测量，预测性能可能会继续改善。
Current research supports the strong potential of structural MRI profiles, even within cross-sectional designs, as a promising method for the discrimination of Alzheimer's Disease (AD) from normal controls and for the prediction of Mild Cognitive Impairment (MCI) progression and conversion to AD. Findings suggest that measures of structural change in mesial and lateral temporal, cingulate, parietal and midfrontal areas may facilitate the assessment of a treatment's ability to halt the progressive structural loss that accompanies clinical decline in MCI. The performance of prediction is likely to continue to improve with the incorporation of measures from other neuroimaging modalities, clinical assessments, and neuromedical biomarkers, as the regional profile of individuals at risk for progression is refined.